Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 183, Issue 1, Pages 23-39
Publisher
Springer Science and Business Media LLC
Online
2020-06-26
DOI
10.1007/s10549-020-05754-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
- (2019) Sherene Loi et al. LANCET ONCOLOGY
- Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1
- (2019) Filippo Montemurro et al. EUROPEAN JOURNAL OF CANCER
- The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
- (2019) Takashi Nakada et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
- (2019) Kenji Tamura et al. LANCET ONCOLOGY
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
- (2019) Udai Banerji et al. LANCET ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Drug-Induced Interstitial Lung Disease: A Systematic Review
- (2018) Sarah Skeoch et al. Journal of Clinical Medicine
- Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
- (2016) Yusuke Ogitani et al. CANCER SCIENCE
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
- (2016) Nadia Harbeck et al. LANCET ONCOLOGY
- Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy
- (2015) Carlos Acevedo-Gadea et al. BREAST CANCER RESEARCH AND TREATMENT
- mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm
- (2015) Annelieke E.C.A.B. Willemsen et al. INTERNATIONAL JOURNAL OF CANCER
- Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
- (2015) Sara A Hurvitz et al. LANCET ONCOLOGY
- Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis
- (2014) Véronique Diéras et al. JOURNAL OF CLINICAL ONCOLOGY
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
- (2014) Nadia Howlader et al. JNCI-Journal of the National Cancer Institute
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
- (2013) Sara A. Hurvitz et al. BREAST CANCER RESEARCH AND TREATMENT
- HER2 Evaluation and Its Impact on Breast Cancer Treatment Decisions
- (2011) K.A.B. Goddard et al. Public Health Genomics
- Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients
- (2011) Bing-He Xu et al. Chinese Journal of Cancer
- A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer
- (2010) Agnieszka Jagiello-Gruszfeld et al. ONCOLOGY
- Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
- (2009) K. L. Blackwell et al. ANNALS OF ONCOLOGY
- An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer
- (2009) G. Capri et al. ANNALS OF ONCOLOGY
- Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer
- (2009) Jeffrey R. Infante et al. Clinical Breast Cancer
- Interstitial lung disease guideline
- (2008) A U Wells et al. THORAX
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now